News
Are you interested in learning about how to license from or collaborate with the NIH? Since the 1970s, the Intramural Research Program (IRP) has served as the in-house research and clinical arm of the NIH. Despite our success, many potential industry collaborators and licensees still see NIH solely
Age-related macular degeneration (AMD) affects approximately 200 million people worldwide and is the leading cause of blindness in all developed countries. Identifying eyes at high risk of progression to late-stage AMD would allow timely medical treatments, lifestyle interventions, more tailored
Ellipsoid zone (EZ) loss has been proposed as evidence of progression of several retinal degenerative diseases, including, but not limited to, retinitis pigmentosa and hydroxychloroquine (HCQ)-induced retinal toxicity. HCQ is a first-line drug used to treat autoimmune diseases such as systemic lupus
Glaucoma is one of the world’s leading causes of irreversible blindness, and currently, no therapies exist to directly protect retinal ganglion cells (RGC) from degradation and loss. NIH inventors have developed a method to treat glaucoma using exosomes derived from bone marrow-derived mesenchymal